Bortezomib (PS-341)

目录号:S1013 别名: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。

规格 价格 库存 购买数量  
RMB 571.94 现货
RMB 2188.92 现货
RMB 5488.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献149篇:

客户使用该产品的25个实验数据:

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外研究

Bortezomib,一种硼酸二肽,是一种26S蛋白酶体的高选择性可逆抑制剂,其作用于错误折叠蛋白的降解,并且对细胞周期的调控是必要的。暴露于Bortezomib能够稳定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制剂κB-α,这防止了核因子κB诱导的细胞存活途径的激活。Bortezomib也会促进促凋亡c-Jun-NH2末端激酶,以及内质网应激反应的激活。这些细胞蛋白水平的改变导致对增殖,迁移的抑制,和癌细胞凋亡的促进。[2] Bortezomib能够渗透到细胞,并抑制蛋白酶体介导的细胞内长寿蛋白水解,抑制50%蛋白质水解的浓度为∼0.1 μM。Bortezomib对衍生自美国国家癌症研究所(NCI)多重人类肿瘤的一组60个癌细胞系的IC50值为7 nM。PC-3细胞用Bortezomib (100 nM)处理8小时导致细胞积聚在G2-M期,相应的G1期细胞数量减少。Bortezomib在24和48小时杀死PC-3细胞,IC50分别为100和20 nM。Bortezomib治疗16-24小时后诱导细胞核缩合。Bortezomib在低至100 nM浓度下以时间依赖的方式导致PARP裂解,在处理24小时后产生效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M4HaR2N6fG:2b4jpZ{BCe3OjeR?= M3rwd|UxKM7:TR?= M3;3UFQ5KGh? NFXZZnpFVVOR NHm2NllMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm NXXJ[Gl4OTB2OUm2OFM>
OVCA 429 MlXESpVv[3Srb36gRZN{[Xl? MV2zNFAhdk1? NX;mSXk3PDhiaB?= NF\TXFRFVVOR NIHB[JVFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> MVSxNFk6QTd4Nh?=
RPMI8226 M3LWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXPemxOOTByIH7N M2DLTlQ5KGh? NGjCW|ZFVVOR NFO3OnhKSzVyPUOwJI5O MW[xNVMxPjR6OR?=
Dox40 NEWxV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K5UFExOCCwTR?= MWi0PEBp MomwSG1UVw>? MWLJR|UxRTRyIH7N NXiyUW8yOTF|ME[0PFk>
MR20 NYDmW2JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnNW|gyODBibl2= M3L5XlQ5KGh? MlnISG1UVw>? MlKyTWM2OD1{MDDuUS=> NXfQNXdHOTF|ME[0PFk>
LR5 M{DsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;EbFExOCCwTR?= NIrnbXg1QCCq M3T1bWROW09? M1n5b2lEPTB;MkCgcm0> Mn24NVE{ODZ2OEm=
U266 NWOzbFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq3RWEyODBibl2= MoT6OFghcA>? NF65WXJFVVOR NX3mNXZOUUN3ME2zJI5O M4fqOFEyOzB4NEi5
IM-9 NF\GcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInaXWUyODBibl2= MVu0PEBp NYnxeZFzTE2VTx?= NWrBOpMzUUN3ME22JI5O MljSNVE{ODZ2OEm=
Hs Sultan Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf6NVAxKG6P MoHDOFghcA>? NG\PPZdFVVOR NFiwOo1KSzVyPUKwJI5O M3LCcFEyOzB4NEi5
PAM-LY2 M171XGZ2dmO2aX;uJGF{e2G7 NGjsWI0yODBibl2= NXfqUXpnOTJiaB?= MVrEUXNQ M3X2bmlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u MWOxNVM2ODlzMx?=
PAM 212 M3fxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNFAhdk1? M1TtWVczKGh? NVnMXFN6TE2VTx?= M3PtSmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NH;LXogyOTN3MEmxNy=>
PAM-LY2 NYK4TmF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLZdIY1OTByIH7N MkLhO|IhcA>? NUXSOVVCTE2VTx?= MoDRTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NXLxN2lJOTF|NUC5NVM>
B4B8 NX\oVHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fTfFExOCCwTR?= M{LmdFczKGh? NHy0fohFVVOR NIe2dFlKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NVrDO4FxOTF|NUC5NVM>
B7E3 NXrsU4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP5PZRSOTByIH7N MV23NkBp MmfDSG1UVw>? MWnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M1PVSVEyOzVyOUGz
UM-SCC-9 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\SUW1yOTByIH7N M1y2OVczKGh? NXHOdWY2TE2VTx?= NU\1N5drUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NVjCOJprOTF|NUC5NVM>
UM-SCC-11B NFLNO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X0PVExOCCwTR?= NFnmepg4OiCq M1LOb2ROW09? MoL3TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MnrGNVE{PTB7MUO=
H460 MkjoSpVv[3Srb36gRZN{[Xl? NFfo[XQyOCEQvF2= M1HMZlI1KGh? MX7EUXNQ MUjJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 MmjoNVI1QTJzMUe=
U266 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDzN3I2ODBibnevcYw> NV\UeWM{PDhiaB?= MlPSSG1UVw>? NG\MbmNKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIL2ZlEyOjZ|MU[xPS=>
ARH77 NH3D[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHMOVAxKG6pL33s MkDvOFghcA>? NV;zWGs{TE2VTx?= NITDXW1KdmirYnn0d{Bk\WyuIHfyc5d1cA>? NWTJfGRpOTJ4M{G2NVk>
WAD-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Rbpk2ODBibnevcYw> MXK0PEBp MVHEUXNQ M{jnV2lvcGmkaYTzJINmdGxiZ4Lve5Rp M1\3XFEzPjNzNkG5
U266/LR7 M1nrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXXOVAxKG6pL33s MYG0PEBp MUfEUXNQ NF73fHhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M2XIPFEzPjNzNkG5
U266/dox4 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvN[lg2ODBibnevcYw> M1i0RlQ5KGh? NFLRepZFVVOR NXrDdIN6UW6qaXLpeJMh[2WubDDndo94fGh? NVrl[nlDOTJ4M{G2NVk>
RPMI8226/LR5 M4TkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfOOVAxKG6pL33s NXTVSoxwPDhiaB?= MlTrSG1UVw>? NHe1WmhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MnW5NVI3OzF4MUm=
H460 NGnCWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHXNVAh|ryP MVm3NkBp NILyOmJFVVOR MXnJR|UxRTFyMDDuUS=> MUCxNlY{OTZ{MB?=
H358 M2LsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3IfGpUOTBizszN MnLYO|IhcA>? NXG5eYYyTE2VTx?= Mk[xTWM2OD15MDDuUS=> MUexNlY{OTZ{MB?=
H322 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDNVAh|ryP NILqN3E4OiCq M1O0d2ROW09? NX\jXlJlUUN3ME22NlAhdk1? NI\LTY4yOjZ|MU[yNC=>
H460 NE[wPVhHfW6ldHnvckBCe3OjeR?= NWnFdnlnOTByIH7N NGTIbZYzPCCq NGLqfmhFVVOR M4n2S2lv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? MmDrNVI3OzF4MkC=
LNCap-Pro5 NW\UfZl7TnWwY4Tpc44hSXO|YYm= NWjuRphEOSEQvF2= NH;2bZg1KGh? MW\EUXNQ NVnsVVg4W3SjYnnsbZpmeyCyNUO= NXzE[Gp5OTR4MUK1N|I>
T29 NITCN49CeG:ydH;zbZMhSXO|YYm= NUjSd2J{PTBibl2= NXzu[WtiPDhiaDC= MVHEUXNQ NX;pb5lbUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWD3dncxOTZ5N{ixO|k>
T29Kt1 M{XWTGFxd3C2b4Ppd{BCe3OjeR?= NIPWXos2OCCwTR?= NX7lWYJyPDhiaDC= MWHEUXNQ M2XifGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnX6NVY4PzhzN{m=
HCT116 NIrwXmlCeG:ydH;zbZMhSXO|YYm= Mm\lOVAhdk1? MWW0PEBpKA>? MkLtSG1UVw>? MorZTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3;ufFE3Pzd6MUe5
HKe-3 M2S5eGFxd3C2b4Ppd{BCe3OjeR?= NYfpdWJrPTBibl2= NU\hU2U3PDhiaDC= NVLuWFZWTE2VTx?= M2fpcWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MoD0NVY4PzhzN{m=
NB-1691 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexJO69VQ>? NYqzZ2tyPzJiaB?= M1\tTWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NV3acllROTd4OEm2PFQ>
CHLA-255 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfyOpkyKM7:TR?= NIfBOFM4OiCq MU\Jcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? NGPyTXMyPzZ6OU[4OC=>
SK-N-AS M33DZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCfGUyKM7:TR?= MnrKO|IhcA>? MlfXTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= MUmxO|Y5QTZ6NB?=
NB-1691 MmnNSpVv[3Srb36gRZN{[Xl? M1HyblExKG6P MWeyOEBp MX3TbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl NXvSdlA2OTd4OEm2PFQ>
CHLA-255 Moe2SpVv[3Srb36gRZN{[Xl? MoX2NVAhdk1? MVSyOEBp NYfsNlUzVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= NHXaVYgyPzZ6OU[4OC=>
RPMI 8226 MXvGeY5kfGmxbjDBd5NigQ>? MojBNlAhdk1? NX;wc|JKQCCq M2HjfnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 Ml3jNVk1OzZyNUC=
MM.1S NF7t[FRHfW6ldHnvckBCe3OjeR?= MoXCNlAhdk1? NIXNXWQ5KGh? MmjYV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M37aZVE6PDN4MEWw
U266 MWTGeY5kfGmxbjDBd5NigQ>? Ml7tNlAhdk1? M1LxblghcA>? NXjRfXlXW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MV2xPVQ{PjB3MB?=
OPM1 NILhWIRHfW6ldHnvckBCe3OjeR?= MXOyNEBvVQ>? NUPKR3J{QCCq MlXaV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M3LSSlE6PDN4MEWw
INA6 NX7UfJBVTnWwY4Tpc44hSXO|YYm= MnH4NlAhdk1? MV24JIg> Ml\WV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NYPlb3FuOTl2M{[wOVA>
OPM2 M1y4R2Z2dmO2aX;uJGF{e2G7 NInPVpgzOCCwTR?= NULqOWFNQCCq MWDTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NXHRU2VsOTl2M{[wOVA>
RPMI 8226 MX\GeY5kfGmxbjDBd5NigQ>? MXqyNEBvVQ>? MVS4JIg> NV3M[mM6UW6mdXPld{BFVkFic4nueIhme2m| MYGxPVQ{PjB3MB?=
BaF/3 M2\RSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLTd5EyODBibl2= NI\6W241QCCq NV7VTG06UUN3ME22MlIhdk1? NF7idJYzODNyNU[5Ni=>
BaF/3-p210 NWDoe4hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hse|ExOCCwTR?= MnfjOFghcA>? MYDJR|UxRTRwNzDuUS=> NVHVPHNJOjB|MEW2PVI>
TCC-S MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNFAhdk1? MUi0PEBp NWPDPIlJUUN3ME2yMlghdk1? NUXYe45qOjB|MEW2PVI>
BaF/3 NWnlfGVDTnWwY4Tpc44hSXO|YYm= NFq4SI43KG6P NFy1[Hc1QCCq MmixTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 NUDFNoRZOjB|MEW2PVI>
BaF/3-p210 MoTySpVv[3Srb36gRZN{[Xl? NFf0Zms3KG6P M4\sVlQ5KGh? NE\kcXFKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MnTGNlA{ODV4OUK=
BaF/3-p210 NUfIU2tQTnWwY4Tpc44hSXO|YYm= MYS2JI5O MVeyOEBp NFLOZmRT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= MViyNFMxPTZ7Mh?=
Raji NFj5RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37kb|Eh|ryP NUm4eIZkOjRiaB?= NUjId|ZRWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MV6yNVE4ODl6OB?=
LCL-1 NY\Yd5FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PLUFEh|ryP MoXTNlQhcA>? M2fMdXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUeyNVE4ODl6OB?=
LCL-2 NEK2S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZNYxYOSEQvF2= MmewNlQhcA>? NVzM[3NyWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NEL2PHczOTF5MEm4PC=>
BJAB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj1NUDPxE1? MmHhNlQhcA>? M3fC[HJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MkLHNlEyPzB7OEi=
SNT-13 M1vDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fwR|Eh|ryP NHnv[WczPCCq NEDpUGtT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MV[yNVE4ODl6OB?=
SNT-16 NWrYUZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HFSlEh|ryP Mor3NlQhcA>? MoT0VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MUSyNVE4ODl6OB?=
Jurkat NF3mUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDsWooyKM7:TR?= MWOyOEBp MUHS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MUCyNVE4ODl6OB?=
KAI-3 NUfwZY5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Zc3dLOSEQvF2= NVTsPG1lOjRiaB?= M1u3cHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= Ml;QNlEyPzB7OEi=
SNK-6 M1TFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXuNUDPxE1? MkLtNlQhcA>? MWfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MkPaNlEyPzB7OEi=
KHYG-1 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDwbJgyKM7:TR?= NGfOOGczPCCq M{DKN3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MlKzNlEyPzB7OEi=
SNT-16 M1PwWWFxd3C2b4Ppd{BCe3OjeR?= M16xXVEh|ryP NV7CfZNOPiCq M4TMR2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MniwNlEyPzB7OEi=
Jurkat NFXGU4ZCeG:ydH;zbZMhSXO|YYm= NWTN[Wt6OSEQvF2= MoTIOkBp NGTDV2pKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGLZZVkzOTF5MEm4PC=>
KAI-3 Mnq5RZBweHSxc3nzJGF{e2G7 Ml;2NUDPxE1? NFz4ZpA3KGh? MVPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkPMNlEyPzB7OEi=
KHYG-1 M{PuWmFxd3C2b4Ppd{BCe3OjeR?= M1f5U|Eh|ryP NUXIXWt1PiCq MWjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXOyNVE4ODl6OB?=
SNT-13 MYXBcpRqfmm{YXygRZN{[Xl? M1zUPFEh|ryP NYXzV4FUOjRiaB?= NGXpT2RKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NF7leoczOTF5MEm4PC=>
SNT-16 M{e2SmFvfGm4aYLhcEBCe3OjeR?= M3XFR|Eh|ryP NHPCcoczPCCq MWPJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M4nPTlIyOTdyOUi4
KAI-3 M325fmFvfGm4aYLhcEBCe3OjeR?= MWexJO69VQ>? MU[yOEBp NGH2WZVKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NEjiW3QzOTF5MEm4PC=>
SNK-6 MVHBcpRqfmm{YXygRZN{[Xl? NXK4dFR4OSEQvF2= MlnFNlQhcA>? NVXoOYlPUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MU[yNVE4ODl6OB?=
RAW 264.7 NVn6S5dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\6NVAxKG6P NXXafoZ4PDhiaB?= NVfFcWxQWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MUiyNlQzPzF3NB?=
A375 M1XGTGFxd3C2b4Ppd{BCe3OjeR?= MnTKNVAhdk1? MnHsNlQhcA>? MlPLTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnjNNlMxPzlyOEO=
BLM MojlRZBweHSxc3nzJGF{e2G7 MXixNEBvVQ>? NW\VU4M6OjRiaB?= MlSwTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlPBNlMxPzlyOEO=
A375 NHzSTWpCfXSxcHjh[5khSXO|YYm= MWqxNEBvVQ>? NYX0c3V{OTJiaB?= NGjOd5RKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NULiV2JtOjNyN{mwPFM>
BLM MULBeZRweGijZ4mgRZN{[Xl? MV6xNEBvVQ>? MkjPNVIhcA>? NIe2SGZKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NYH2R3NnOjNyN{mwPFM>
H1299 M1PJTmFxd3C2b4Ppd{BCe3OjeR?= MmnIPFAhdk1? NFHlfVEzPCCq MkG5SG1UVw>? NGHVTVVU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= NHXURpkzPTN{M{[5Ny=>
Hut-78 MXvGeY5kfGmxbjDBd5NigQ>? M4\CNVExOCCwTR?= NIr2elkzPCCq M3vKbmROW09? NFrkPHBFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFyIHX4dJJme3Orb36= NYT3PFNSOjV4OEGzN|U>
H9 M2flRmZ2dmO2aX;uJGF{e2G7 MWWxNFAhdk1? NUDGPHZMOjRiaB?= NHrofoJFVVOR MYnEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? NVHrOnRwOjV4OEGzN|U>
HH NF7UdoZHfW6ldHnvckBCe3OjeR?= Ml;HNVAxKG6P NWjIfIxYOjRiaB?= NUfmTmFiTE2VTx?= Mofv[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w MlS0NlU3QDF|M{W=
Hut-78 MYLNbYdz[XSrb36gRZN{[Xl? MY[xNFAhdk1? MUeyOEBp NIj0PW9FVVOR NYThTpRrWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> MVOyOVY5OTN|NR?=
HH M4rKTG1q\3KjdHnvckBCe3OjeR?= NG\LRnkyODBibl2= Mme0NlQhcA>? MYfEUXNQ MnHrVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= NGX5VHYzPTZ6MUOzOS=>
U937 MoG0SpVv[3Srb36gRZN{[Xl? MXmxNFAhdk1? MW[2JIg> NIDiWZZKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| M3;QVVI2PzlzNEe3
human PBMC NWqxeJZvTnWwY4Tpc44hSXO|YYm= NXTHelR6OTByIH7N MmK5NlQhcA>? NUnwSY1FUW6mdXPld{BKVC16IILlcIVie2V? Ml3PNlU4QTF2N{e=
ES6 NHXsR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMECyNUBvVQ>? MmjyV2FPT0WU
SK-UT-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWwXmpyUUN3ME2wMlE3OyCwTR?= MX3TRW5ITVJ?
SH-4 NYXPd4lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMUezJI5O NHPvXVBUSU6JRWK=
TE-9 M1jzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPiR5dKSzVyPUCuNVgzKG6P NGj2UlhUSU6JRWK=
A253 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXCcYhKUUN3ME2wMlIxQCCwTR?= Mlj1V2FPT0WU
no-10 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLDZmtKSzVyPUCuNlEhdk1? NWrOZ4hTW0GQR1XS
MMAC-SF MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkG2JI5O MWrTRW5ITVJ?
A101D MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX2bJJ1UUN3ME2wMlIzPSCwTR?= MoroV2FPT0WU
NTERA-S-cl-D1 NYC3WoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMkSzJI5O MVLTRW5ITVJ?
8-MG-BA M4G1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMkWgcm0> NVrE[pNNW0GQR1XS
KNS-42 NGTEVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[3T25OUUN3ME2wMlI2QCCwTR?= MWXTRW5ITVJ?
LXF-289 M2f3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMk[5JI5O NFHETIJUSU6JRWK=
OVCAR-4 NHHoSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjkWVJKSzVyPUCuNlg6KG6P NHTaUohUSU6JRWK=
LOUCY NYDTeFh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMkmzJI5O MX\TRW5ITVJ?
BB65-RCC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjie2JKSzVyPUCuN|A1KG6P Mm\LV2FPT0WU
D-542MG Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\aeINKSzVyPUCuN|I6KG6P NGDkW|RUSU6JRWK=
ONS-76 NXvYblg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwM{Ogcm0> MVfTRW5ITVJ?
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrwRoh1UUN3ME2wMlM{PSCwTR?= NHPxWlhUSU6JRWK=
KS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\pOHBGUUN3ME2wMlM1KG6P MYDTRW5ITVJ?
A388 NFy5c2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvie|FKSzVyPUCuN|U3KG6P MV7TRW5ITVJ?
ES8 NVPWVplET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3eybGlEPTB;MD60JI5O M{WwNXNCVkeHUh?=
MZ2-MEL MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL6SlZlUUN3ME2wMlQxPyCwTR?= NF25N3NUSU6JRWK=
HCC2998 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnVTWM2OD1yLkSxNkBvVQ>? MofTV2FPT0WU
D-247MG Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILLTW5KSzVyPUCuOFE{KG6P Ml\BV2FPT0WU
ACN M1XQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETyVG5KSzVyPUCuOFE4KG6P NYi1eFE6W0GQR1XS
LB2518-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHhOXpEUUN3ME2wMlQzPSCwTR?= MWDTRW5ITVJ?
ES1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXiTWM2OD1yLkSzJI5O NVn3O4NUW0GQR1XS
HCE-T M{XUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX6TWM2OD1yLkSzPUBvVQ>? NFvycYtUSU6JRWK=
OS-RC-2 NHrR[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorPTWM2OD1yLkS0JI5O M1rWVHNCVkeHUh?=
MFH-ino NFLrSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNESzJI5O M3;MS3NCVkeHUh?=
OCUB-M Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTXTWM2OD1yLkS0O{BvVQ>? NW\pZnc{W0GQR1XS
CP66-MEL M1Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\MSFBMUUN3ME2wMlQ4OyCwTR?= Mkj5V2FPT0WU
LB771-HNC NIDnNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNEe0JI5O MXTTRW5ITVJ?
DSH1 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37xV2lEPTB;MD60PEBvVQ>? MkG0V2FPT0WU
HUTU-80 NVTSXlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG3VFhKSzVyPUCuOVM{KG6P M1nOZ3NCVkeHUh?=
CESS MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\mTWM2OD1yLkWzPEBvVQ>? NEXWSGhUSU6JRWK=
NCI-H747 M2j1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfOW5BKSzVyPUCuOVM6KG6P M2exXnNCVkeHUh?=
HT-144 M2\NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PUOWlEPTB;MD61O|Yhdk1? M2i4XnNCVkeHUh?=
COLO-829 NXTSOlNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e1O2lEPTB;MD62NVQhdk1? MmqzV2FPT0WU
A4-Fuk MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNkKzJI5O NFfaR41USU6JRWK=
GI-ME-N MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNkO0JI5O MmfRV2FPT0WU
LB831-BLC Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vVXWlEPTB;MD62OFEhdk1? NWnu[XFPW0GQR1XS
HOP-62 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;5OXZrUUN3ME2wMlY1PyCwTR?= MkjCV2FPT0WU
BB49-HNC NIrXdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnLTWM2OD1yLk[1NkBvVQ>? NEn4d45USU6JRWK=
D-336MG M1;kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf4boFKSzVyPUCuOlU4KG6P MkDCV2FPT0WU
TK10 NFi0d|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DWR2lEPTB;MD62O|khdk1? MkGwV2FPT0WU
Ramos-2G6-4C10 NVW2NINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwNkmzJI5O Mn7jV2FPT0WU
LB373-MEL-D NGTWXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojHTWM2OD1yLkegcm0> NGW3V2xUSU6JRWK=
SF126 NGD4TVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwN{CxJI5O MVjTRW5ITVJ?
UACC-257 M3nCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37acmlEPTB;MD63NUBvVQ>? MVHTRW5ITVJ?
KINGS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwN{KyJI5O M3TZO3NCVkeHUh?=
LS-513 M13pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfqTWM2OD1yLkezPUBvVQ>? NITNWVRUSU6JRWK=
GI-1 NVjsbnVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGwdXF2UUN3ME2wMlc3PCCwTR?= M3PrZXNCVkeHUh?=
ES7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPObnBKSzVyPUCuO|Y3KG6P MXfTRW5ITVJ?
LB2241-RCC NVzjfFE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OwN2lEPTB;MD64NFQhdk1? M{O0U3NCVkeHUh?=
D-263MG NXvsU49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVToWY9TUUN3ME2wMlgxPyCwTR?= MXHTRW5ITVJ?
SW684 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKwWHhOUUN3ME2wMlgzOSCwTR?= MWPTRW5ITVJ?
ML-2 NULjUoVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwOEKxJI5O NYnxc45vW0GQR1XS
SK-LMS-1 M1fx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHQTZdKUUN3ME2wMlg2PCCwTR?= M4Xpd3NCVkeHUh?=
TE-5 NIPIS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn2WYV{UUN3ME2wMlg3PSCwTR?= MWLTRW5ITVJ?
QIMR-WIL NE[ydGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDBToliUUN3ME2wMlg5QSCwTR?= M3;6SnNCVkeHUh?=
NCI-H1355 NVnKe5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnMfZY{UUN3ME2wMlg6PSCwTR?= Mo\4V2FPT0WU
SNB75 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5cXdKSzVyPUCuPVEzKG6P NGfYfFNUSU6JRWK=
RXF393 NF3kfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHib3JKSzVyPUCuPVE1KG6P M1zjUXNCVkeHUh?=
IST-MEL1 NV;NVJJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW1dpRqUUN3ME2wMlkyPyCwTR?= MVPTRW5ITVJ?
SF268 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwOUKzJI5O Mn;4V2FPT0WU
KALS-1 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\yTWM2OD1yLkmyOUBvVQ>? MV;TRW5ITVJ?
HC-1 NIS4OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPNcItSUUN3ME2wMlk4PSCwTR?= NFnmOVFUSU6JRWK=
SW872 M4S2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\nTWM2OD1yLkm5OkBvVQ>? MVHTRW5ITVJ?
PSN1 NHHDcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HUcmlEPTB;MT6wNUBvVQ>? NFqx[plUSU6JRWK=
TE-1 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTNTWM2OD1zLkCzJI5O M1rzfnNCVkeHUh?=
TE-10 NULBVnpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7pTWM2OD1zLkCzJI5O MV7TRW5ITVJ?
RKO MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwME[gcm0> NFvQWXdUSU6JRWK=
LC-2-ad NEHX[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljoTWM2OD1zLkC4JI5O NWG3S4RJW0GQR1XS
SK-MM-2 NHjXUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XWZmlEPTB;MT6wPUBvVQ>? MULTRW5ITVJ?
VA-ES-BJ NETLPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwMEmgcm0> NH;teYNUSU6JRWK=
MZ7-mel M{DBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrWTWM2OD1zLkC5JI5O Mn30V2FPT0WU
D-392MG NYn0S3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCTWM2OD1zLkGgcm0> NVXCb2NCW0GQR1XS
CCRF-CEM MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKTYtpUUN3ME2xMlE{KG6P NWHCZ3ZuW0GQR1XS
EM-2 NULzfXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjqTWM2OD1zLkG2JI5O M1TMZnNCVkeHUh?=
HAL-01 M17vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PsOGlEPTB;MT6xPEBvVQ>? NHH1cWNUSU6JRWK=
TE-8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle4TWM2OD1zLkG5JI5O NVvsOo11W0GQR1XS
NCI-H1882 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLFR|lqUUN3ME2xMlIhdk1? NYfUW|FvW0GQR1XS
Daudi MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLaTWM2OD1zLkKyJI5O NITVVHBUSU6JRWK=
BL-41 M3nzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ETWM2OD1zLkK1JI5O MVjTRW5ITVJ?
SR NHXjRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXuZ|NDUUN3ME2xMlI2KG6P NEDDSGZUSU6JRWK=
KM12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\BbW5KSzVyPUGuNlchdk1? NIrMVlFUSU6JRWK=
K5 NFHMNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLWTWM2OD1zLkK4JI5O M3fQeXNCVkeHUh?=
A3-KAW NYSwd4dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P6RWlEPTB;MT6yPEBvVQ>? M4jYfnNCVkeHUh?=
CMK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS0SHlKSzVyPUGuNlkhdk1? MoTYV2FPT0WU
Calu-6 NFv1bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwMkmgcm0> M1PGNHNCVkeHUh?=
IST-SL2 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwM{Ggcm0> NWDoPHVtW0GQR1XS
OPM-2 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPVbpJKSzVyPUGuN|Mhdk1? NYmybIVJW0GQR1XS
DU-4475 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{[gcm0> MoTOV2FPT0WU
ECC12 NIPRfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXncXZKSzVyPUGuN|chdk1? NEX0VGFUSU6JRWK=
L-540 M13NS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHUTWM2OD1zLkO3JI5O M1vIXnNCVkeHUh?=
CAS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjIdFd3UUN3ME2xMlM4KG6P NV;NdWdWW0GQR1XS
PF-382 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrPTWM2OD1zLkS3JI5O NFzpc2VUSU6JRWK=
LS-411N MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTVVINKSzVyPUGuOVMhdk1? NEfDfo1USU6JRWK=
NCI-H69 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwNUSgcm0> MUfTRW5ITVJ?
NB12 NITwXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\wdHNXUUN3ME2xMlU3KG6P M2TsUnNCVkeHUh?=
HEL MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDpSJRKSzVyPUGuOlEhdk1? MVHTRW5ITVJ?
GCIY MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLs[G5FUUN3ME2xMlYzKG6P M2SxUHNCVkeHUh?=
EHEB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHmU4xtUUN3ME2xMlY4KG6P M33O[HNCVkeHUh?=
TGBC1TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwN{Ggcm0> NEHLVGZUSU6JRWK=
KURAMOCHI M2rsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwN{Kgcm0> MkHTV2FPT0WU
U-266 NXTzfGhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwN{[gcm0> NXHDUWtDW0GQR1XS
LC4-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL6N|hZUUN3ME2xMlc6KG6P NGjzVoRUSU6JRWK=
NCI-H2126 NH3wU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;vXINKSzVyPUGuPEBvVQ>? MYrTRW5ITVJ?
NCI-H1092 M3TUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTRTWM2OD1zLkigcm0> MmnWV2FPT0WU
GB-1 NYXwempDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrWUnhbUUN3ME2xMlgyKG6P NH3BfGFUSU6JRWK=
MV-4-11 NYO0TYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nuRWlEPTB;MT64NkBvVQ>? NVrjNHkxW0GQR1XS
Becker M1OwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwOEOgcm0> NGO3VJJUSU6JRWK=
MPP-89 NFP0dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jZTWlEPTB;MT64PUBvVQ>? MnLwV2FPT0WU
BE-13 NVzRdm9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHoOmpKSzVyPUGuPVMhdk1? NIHWdYtUSU6JRWK=
697 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P5T2lEPTB;MT65PUBvVQ>? NWr2XI5LW0GQR1XS
NKM-1 NGHYTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrWJVCUUN3ME2yJI5O NITo[IlUSU6JRWK=
NB13 NHLHZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJibl2= MVjTRW5ITVJ?
LS-123 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\hR5lKSzVyPUKuNFIhdk1? M2CyOXNCVkeHUh?=
NB17 M2Gx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLmU|lKSzVyPUKuNFQhdk1? MnTqV2FPT0WU
LAN-6 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS4NXJDUUN3ME2yMlA2KG6P M1SzbnNCVkeHUh?=
EW-24 NWX4SWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PRdGlEPTB;Mj6wPEBvVQ>? MlniV2FPT0WU
NOS-1 MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnte|hKSzVyPUKuNVEhdk1? NXzFbJFOW0GQR1XS
BL-70 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PZUWlEPTB;Mj6xNkBvVQ>? M1XNcnNCVkeHUh?=
GT3TKB MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjXdFVnUUN3ME2yMlEzKG6P NYPKd296W0GQR1XS
HH MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[xTWM2OD1{LkGzJI5O MV7TRW5ITVJ?
KE-37 M3\IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;GTWM2OD1{LkGzJI5O M1rZPHNCVkeHUh?=
MOLT-4 NFrVb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMUOgcm0> MV7TRW5ITVJ?
EKVX NVrTd|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJwMUSgcm0> M4myXHNCVkeHUh?=
KGN Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nCVWlEPTB;Mj6xOUBvVQ>? NIrQellUSU6JRWK=
ES4 NEK2WI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nW[WlEPTB;Mj6xOkBvVQ>? NGrOUVJUSU6JRWK=
SJSA-1 NXWxNVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwMkGgcm0> NXu4WXZ2W0GQR1XS
KMOE-2 NX33SotkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj6O4VCUUN3ME2yMlI{KG6P NH3EO21USU6JRWK=
NB5 NYH5fIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XlV2lEPTB;Mj6yO{BvVQ>? NULXOoxOW0GQR1XS
BC-1 NGfOS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jwdmlEPTB;Mj6zNUBvVQ>? MXvTRW5ITVJ?
NB10 M2n5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\2TWM2OD1{LkOyJI5O M1noe3NCVkeHUh?=
RPMI-8226 NFrXN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXqTWM2OD1{LkO1JI5O NFnNd|ZUSU6JRWK=
SCC-3 NW[wNVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYTWM2OD1{LkO3JI5O NYHxSYFSW0GQR1XS
ARH-77 NWXIZopYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXZTWM2OD1{LkO4JI5O NFLYelJUSU6JRWK=
NCI-H748 NF\WUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwM{mgcm0> NHzRXGRUSU6JRWK=
KU812 NYP0N2ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnHTohKSzVyPUKuOFIhdk1? NILvUIVUSU6JRWK=
NCI-H64 NHv6elNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HpSGlEPTB;Mj60OEBvVQ>? Mm\tV2FPT0WU
NB69 NXznNYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HzUWlEPTB;Mj60OkBvVQ>? M3T3eHNCVkeHUh?=
KNS-81-FD NVe1dGRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnZ[VExUUN3ME2yMlQ5KG6P M3njN3NCVkeHUh?=
LB1047-RCC NYPLOG1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXBcpRKSzVyPUKuOVchdk1? NVfLSllEW0GQR1XS
EB-3 NUXmb2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:2WXlXUUN3ME2yMlY3KG6P MkDKV2FPT0WU
Mo-T NV22eYZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[zTWM2OD1{Lke0JI5O NEn5NlJUSU6JRWK=
EW-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULBTog6UUN3ME2yMlc2KG6P NX3LR4tpW0GQR1XS
CTV-1 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjHNWtKSzVyPUKuPEBvVQ>? NFy1cpJUSU6JRWK=
ETK-1 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETEb4JKSzVyPUKuPFQhdk1? MmP0V2FPT0WU
C2BBe1 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\KdGlEPTB;Mj64PUBvVQ>? NGj1c|BUSU6JRWK=
MOLT-16 M3rnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[1eJRKSzVyPUKuPFkhdk1? MoTxV2FPT0WU
SW954 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjzR5NPUUN3ME2yMlkhdk1? MVrTRW5ITVJ?
HT NUS5Xo1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD2TWM2OD1|LkCyJI5O NGfvfolUSU6JRWK=
KARPAS-299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwME[gcm0> Ml\SV2FPT0WU
MONO-MAC-6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPuTWM2OD1|LkGgcm0> MoX5V2FPT0WU
CGTH-W-1 M33iZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInZRmpKSzVyPUOuNUBvVQ>? M2i3TnNCVkeHUh?=
SK-PN-DW M3u0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjjNWtKSzVyPUOuNVQhdk1? NYm4XWtRW0GQR1XS
CW-2 M13pTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf3fFNKSzVyPUOuNlEhdk1? Mn3IV2FPT0WU
SK-N-DZ NHnZPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXRoNNUUN3ME2zMlI3KG6P MkHPV2FPT0WU
NEC8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjmTWM2OD1|LkO1JI5O MkLyV2FPT0WU
LB996-RCC NUDzSG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwNDDuUS=> MWLTRW5ITVJ?
DB NXjTcndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLETWM2OD1|LkSxJI5O NV\FSW97W0GQR1XS
TE-15 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX1bXMzUUN3ME2zMlQ{KG6P M4XZdnNCVkeHUh?=
COR-L88 M1m3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HJTmlEPTB;Mz60O{BvVQ>? M2nHeXNCVkeHUh?=
LAMA-84 NYnCSYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTNwNEmgcm0> NGT6ZY9USU6JRWK=
MEG-01 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2noSWlEPTB;Mz60PUBvVQ>? MljYV2FPT0WU
LOXIMVI NEjqbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTsTWM2OD1|LkWgcm0> M33heHNCVkeHUh?=
RPMI-8402 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDwZXVvUUN3ME2zMlUhdk1? MkPKV2FPT0WU
KARPAS-45 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjo[2RKSzVyPUOuOVQhdk1? M4\jZ3NCVkeHUh?=
HCC1187 NYHuXWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGxTWM2OD1|LkW0JI5O NYTxbZVmW0GQR1XS
MZ1-PC NYTOTJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwNUSgcm0> NFm4WmFUSU6JRWK=
no-11 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknnTWM2OD1|LkW1JI5O MornV2FPT0WU
EVSA-T M{fxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnQUVRKSzVyPUOuOkBvVQ>? NGTueIlUSU6JRWK=
DJM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL4TWM2OD1|Lk[zJI5O M3\reHNCVkeHUh?=
COLO-684 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXVUWppUUN3ME2zMlY3KG6P MYHTRW5ITVJ?
NMC-G1 M133[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG5TWM2OD1|Lk[4JI5O MVzTRW5ITVJ?
LC-1F NET0S3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X1RWlEPTB;Mz63OEBvVQ>? MmfRV2FPT0WU
RL95-2 M3LnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTNwN{mgcm0> MkHjV2FPT0WU
COLO-320-HSR NVi5So57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7jc2JKSzVyPUOuPVIhdk1? NGnkV3VUSU6JRWK=
RCC10RGB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnUTGpKSzVyPUOuPVMhdk1? MWHTRW5ITVJ?
HD-MY-Z NH21b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PSTWlEPTB;Mz65N{BvVQ>? MWHTRW5ITVJ?
NCI-H2141 M1jJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzze2RxUUN3ME20MlA2KG6P M4PEXHNCVkeHUh?=
K-562 NF3mUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i2d2lEPTB;ND6xNkBvVQ>? MYjTRW5ITVJ?
NCI-H1648 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfzW49KSzVyPUSuNVMhdk1? M3TLdnNCVkeHUh?=
OMC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRwMUigcm0> NF7COFFUSU6JRWK=
LB647-SCLC NU\hSGU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TOXGlEPTB;ND6yNkBvVQ>? MXrTRW5ITVJ?
TE-12 NXnEeGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrrTWM2OD12LkK1JI5O NVHkdHdZW0GQR1XS
NOMO-1 NWHwe4t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPFTWM2OD12LkOzJI5O NF;6OmlUSU6JRWK=
Raji NHjaToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37qfmlEPTB;ND60OkBvVQ>? MYDTRW5ITVJ?
NALM-6 NV7PdJVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HBO2lEPTB;ND60PUBvVQ>? MoXWV2FPT0WU
HL-60 NUnO[4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwNkegcm0> MXnTRW5ITVJ?
IST-SL1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PCTGlEPTB;ND62PEBvVQ>? NV3McYV3W0GQR1XS
MHH-PREB-1 NFviVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwOE[gcm0> MV;TRW5ITVJ?
MHH-NB-11 NIjJeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfNeVNKSzVyPUSuPVEhdk1? MoDUV2FPT0WU
JiyoyeP-2003 NGrGOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjvOFJkUUN3ME21JI5O NUTDZXN2W0GQR1XS
SBC-1 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jpR2lEPTB;NT6wNUBvVQ>? M37nWHNCVkeHUh?=
CHP-126 NWHje3RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jO[mlEPTB;NT6wOkBvVQ>? NVf1epA1W0GQR1XS
LU-139 NXLmRY5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwMUOgcm0> MmC5V2FPT0WU
NCI-SNU-5 NGj6e|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jpVmlEPTB;NT6xO{BvVQ>? M4rvOXNCVkeHUh?=
SW962 NH:yZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fwVmlEPTB;NT6yNUBvVQ>? MVfTRW5ITVJ?
EW-1 NELpVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnITWM2OD13LkOxJI5O MYTTRW5ITVJ?
NCI-H1417 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C3[2lEPTB;NT61NUBvVQ>? M3:4bXNCVkeHUh?=
LU-65 M1\BNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnyZ3FKSzVyPUWuPFQhdk1? NWLDXJRsW0GQR1XS
D-502MG NITLWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn3dVRKSzVyPU[uN|chdk1? NGjER|JUSU6JRWK=
BC-3 NXLMXGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LscmlEPTB;Nj62NUBvVQ>? MoDUV2FPT0WU
GDM-1 M4i5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm4dHRKSzVyPU[uO|chdk1? MVPTRW5ITVJ?
NCI-H2196 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu5XZV4UUN3ME22Mlghdk1? Mk\uV2FPT0WU
NB1 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvPd5BIUUN3ME22Mlg5KG6P NWHrfYZpW0GQR1XS
NCI-H345 NXXCTnYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLUTWM2OD15LkKgcm0> NWWxXZllW0GQR1XS
SU-DHL-1 M4ewTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXITWM2OD15LkK0JI5O MWrTRW5ITVJ?
JVM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwMkigcm0> M1rSVnNCVkeHUh?=
LU-134-A MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PJeWlEPTB;Nz6zPUBvVQ>? NFHoVJlUSU6JRWK=
NCI-H1694 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[1TlJVUUN3ME23MlU5KG6P NFLXW3dUSU6JRWK=
NCI-SNU-16 NHvo[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\BZmlEPTB;Nz62OUBvVQ>? MmLFV2FPT0WU
L-363 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi0TWM2OD15Lkegcm0> NHjXWmpUSU6JRWK=
KG-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTqTWM2OD15Lkm0JI5O Mn\oV2FPT0WU
MN-60 NIPSO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvvPJpKSzVyPUiuNVQhdk1? NFrGRpdUSU6JRWK=
NB6 NWDHWJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XOWGlEPTB;OD60PEBvVQ>? NGjIXIVUSU6JRWK=
MLMA NEC1[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H6XWlEPTB;OD64OUBvVQ>? M175TnNCVkeHUh?=
ATN-1 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjxTWM2OD16Lki5JI5O MWjTRW5ITVJ?
SK-NEP-1 NIPwTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTlwMEGgcm0> MWjTRW5ITVJ?
DMS-114 M2fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjXeY1VUUN3ME25MlYzKG6P MXrTRW5ITVJ?
CTB-1 M{jyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTlwNkegcm0> MlPZV2FPT0WU
NCI-H2081 NHXxS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOOmlEPTB;MUCuNFkhdk1? NE\aN2dUSU6JRWK=
ES5 NEHzWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFyLkO4JI5O M1[5PHNCVkeHUh?=
HCC1599 M1fjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\CcGhKSzVyPUGxMlkyKG6P NVXKd5E3W0GQR1XS
NCI-H23 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7tfVBPUUN3ME2xNk4yOiCwTR?= MmnrV2FPT0WU
NCI-H1581 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfqb4h1UUN3ME2xNk4zQCCwTR?= M2m2WHNCVkeHUh?=
JVM-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjsUFhKSzVyPUGyMlk6KG6P NUHsRXp[W0GQR1XS
NCI-SNU-1 NIX5c3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfRb25KSzVyPUGzMlE6KG6P NVnrdmlQW0GQR1XS
NB7 M4DmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G0VWlEPTB;MUWuPVIhdk1? NUX0ToFuW0GQR1XS
JAR NGPRZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljnTWM2OD1zNj6xN{BvVQ>? MYjTRW5ITVJ?
TGW MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4NnFKSzVyPUG2MlQ5KG6P MkLVV2FPT0WU
U-87-MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfKZlFKSzVyPUG2Mlc3KG6P Mm\3V2FPT0WU
NCI-H1436 NFXwdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe4PHNKSzVyPUG3MlAyKG6P MXfTRW5ITVJ?
GOTO NYrkdWtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;uTWM2OD1zNz6wOkBvVQ>? NFvwPI9USU6JRWK=
COLO-800 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPrWoNKSzVyPUG3MlY1KG6P NIDUNpdUSU6JRWK=
MFM-223 NUe5RnJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XBe2lEPTB;MUeuPVEhdk1? NFrweIdUSU6JRWK=
EW-18 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX5dFVKSzVyPUG3Mlk3KG6P Mnj4V2FPT0WU
NB14 NYDj[WFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1zNz65PEBvVQ>? Mnm2V2FPT0WU
EB2 M4HuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF6LkC4JI5O MlOzV2FPT0WU
EoL-1- NFf4dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\lTWM2OD1zOD6zNUBvVQ>? NUXZe28zW0GQR1XS
NCCIT Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF6LkO2JI5O NWrZOHlTW0GQR1XS
DG-75 M17ZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HMfGlEPTB;MUiuOlEhdk1? NWr1UIpwW0GQR1XS
HCC2218 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PzWWlEPTB;MUmuOUBvVQ>? MXrTRW5ITVJ?
TE-6 NVTue|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJyLkC4JI5O NUfXfWZQW0GQR1XS
SF539 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD1{MD62O{BvVQ>? Mn\tV2FPT0WU
NCI-H446 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJzLkG4JI5O Ml;SV2FPT0WU
IST-MES1 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13iPGlEPTB;MkKuO|chdk1? M3vXVXNCVkeHUh?=
NCI-H82 NGfH[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L5cWlEPTB;MkOuNFIhdk1? MmfsV2FPT0WU
HCC2157 M{iwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnLTWM2OD1{Mz6xN{BvVQ>? M2[2dHNCVkeHUh?=
EW-12 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH75PGNKSzVyPUKzMlE4KG6P NWnn[Wl1W0GQR1XS
SIMA M37qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\CNJNKSzVyPUKzMlM5KG6P M4LFdnNCVkeHUh?=
DOHH-2 NFLScIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3rTWM2OD1{Mz60OUBvVQ>? MkLsV2FPT0WU
IM-9 M3u2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XQfGlEPTB;MkOuOVQhdk1? MWPTRW5ITVJ?
EC-GI-10 NVjRR5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInud5VKSzVyPUK0MlI{KG6P NEjlZoFUSU6JRWK=
HDLM-2 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXixcmtFUUN3ME2yOE42PCCwTR?= NWT1e3NoW0GQR1XS
LS-1034 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHGTWM2OD1{NT63OUBvVQ>? MkPHV2FPT0WU
REH NIC2eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD1{Nj60NUBvVQ>? NFHTNI5USU6JRWK=
LU-165 NV3HW3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\HZpBOUUN3ME2yOk44OiCwTR?= NX3GTG1MW0GQR1XS
NH-12 NHfWeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LUb2lEPTB;MkeuOlchdk1? M{jO[3NCVkeHUh?=
WSU-NHL M3jm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ6LkO5JI5O NFHZ[IpUSU6JRWK=
ECC4 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZVnhXUUN3ME2yPE44QSCwTR?= M2fGOXNCVkeHUh?=
OCI-AML2 NWXi[o1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfNTWM2OD1{OT62PUBvVQ>? NWP0ZnZLW0GQR1XS
EW-3 NFLhTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvwepVpUUN3ME2zNE42QSCwTR?= MX7TRW5ITVJ?
NCI-H526 M2H5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj2RoZGUUN3ME2zNk42PCCwTR?= NVy1[ZZXW0GQR1XS
NCI-H719 NWn3TYFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzXTWM2OD1|ND6zNUBvVQ>? MVXTRW5ITVJ?
KARPAS-422 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTScZFKSzVyPUO1MlA1KG6P NXOwbYI5W0GQR1XS
SK-MEL-1 NFfDdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;xVG9KSzVyPUO1MlE4KG6P NFXIenpUSU6JRWK=
ES3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LIWWlEPTB;M{WuNVkhdk1? MkfZV2FPT0WU
UACC-812 NXf1cHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnvRmF{UUN3ME2zOU41PCCwTR?= NYKwN|NzW0GQR1XS
C8166 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN3Lkegcm0> MUTTRW5ITVJ?
MDA-MB-134-VI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jBVWlEPTB;M{WuPFchdk1? MWHTRW5ITVJ?
D-283MED NEDaSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HHUGlEPTB;M{euO|khdk1? MVnTRW5ITVJ?
SHP-77 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHZTWM2OD1|OD6wN{BvVQ>? MWPTRW5ITVJ?
NCI-H2227 NWP2Oo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRyLkS5JI5O NUnaNGJmW0GQR1XS
SKM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37PSWlEPTB;NEKuOlMhdk1? NYexbYMxW0GQR1XS
L-428 NWLEe2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HGc2lEPTB;NEOuPFYhdk1? MVTTRW5ITVJ?
RPMI-6666 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR3Lki5JI5O M3[5WnNCVkeHUh?=
NCI-H716 M2f1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjvNZNKSzVyPUS4MlgyKG6P MkfrV2FPT0WU
DMS-79 M1\6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTVyLkexJI5O M3flfXNCVkeHUh?=
RS4-11 NXG3d4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfDWYdWUUN3ME21NE45QCCwTR?= MVXTRW5ITVJ?
NCI-H720 NV:2XVRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXHS|RYUUN3ME21NU4yOSCwTR?= MYPTRW5ITVJ?
MC-CAR MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjSUHd5UUN3ME21NU42OiCwTR?= MYDTRW5ITVJ?
TALL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTV|LkmxJI5O NFyx[VlUSU6JRWK=
NCI-N87 NI\kc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3wc4JKSzVyPUW0MlE5KG6P NX7ibW9SW0GQR1XS
P30-OHK M3f2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXvTVFKSzVyPUW0MlYyKG6P MmryV2FPT0WU
LP-1 NUm4SZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TGUWlEPTB;NkGuNlghdk1? M371enNCVkeHUh?=
YT NGTHUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\TTWM2OD14MT64JI5O MlGwV2FPT0WU
MRK-nu-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G3VmlEPTB;NkGuPFIhdk1? NEiyd|JUSU6JRWK=
BT-474 NV33cIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZ3IH7N NIr4[pZUSU6JRWK=
NCI-H322M MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\IfZZKSzVyPU[2MlEyKG6P MW\TRW5ITVJ?
NCI-H128 MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmyTWM2OD15ND63O{BvVQ>? M4XMXHNCVkeHUh?=
KMS-12-PE MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfPUo5KSzVyPUe2MlI1KG6P NFXmOYVUSU6JRWK=
KP-N-YS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn3[nhKSzVyPUe2Mlc1KG6P MoLPV2FPT0WU
ALL-PO MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W3RWlEPTB;N{euOlYhdk1? NXS1co94W0GQR1XS
EW-13 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmxUXNKSzVyPUe3Mlc3KG6P M3vBfXNCVkeHUh?=
EW-11 NGq1V2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn36TWM2OD15OD61NkBvVQ>? MkK2V2FPT0WU
SK-N-FI NIXme|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C0W2lEPTB;OECuNkBvVQ>? NV;sRZBvW0GQR1XS
CAL-148 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRThzLki0JI5O NIC1cWJUSU6JRWK=
RL M1flPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTh4LkC5JI5O NImyfYtUSU6JRWK=
AM-38 NUXZSYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTKZXBKSzVyPUi4MlA5KG6P MXTTRW5ITVJ?
RH-1 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vHfGlEPTB;OUmuPFUhdk1? M3\wfHNCVkeHUh?=
NCI-H1770 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfndFNKSzVyPUGwNk41QSCwTR?= Mk\zV2FPT0WU
SIG-M5 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rr[2lEPTB;MUC1MlA3KG6P MV3TRW5ITVJ?
GR-ST MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD4T3B3UUN3ME2xNVMvOzRibl2= NX;D[m9QW0GQR1XS
ST486 NGO5bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\QT2lEPTB;MUG0MlA3KG6P MlvRV2FPT0WU
NCI-H1650 NXXQNIdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTyTWM2OD1zMUWuNlkhdk1? MUPTRW5ITVJ?
MHH-CALL-2 NYGxeYRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXLTWM2OD1zMUWuO{BvVQ>? NF3pdpRUSU6JRWK=
BV-173 NYjIO|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwTWM2OD1zMkKuO|Ehdk1? MXjTRW5ITVJ?
MC116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGixUnRKSzVyPUG0PE45PSCwTR?= M3WwNXNCVkeHUh?=
NCI-H524 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrtTWM2OD1zNUmuNUBvVQ>? NWDmPGFvW0GQR1XS
SCLC-21H NIfaeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF3OT60NUBvVQ>? NVPUO4lkW0GQR1XS
NCI-H1304 NXHBXVZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi5fotJUUN3ME2xOlkvOjFibl2= MmG2V2FPT0WU
NCI-H510A MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF6NT6zO{BvVQ>? NEfPcJpUSU6JRWK=
NCI-H209 NHy3VY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy1UYdQUUN3ME2xPVYvPTJibl2= MYHTRW5ITVJ?
KM-H2 M{i2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\6PIZKSzVyPUG5O{4xPSCwTR?= MUnTRW5ITVJ?
NCI-H1395 NEXMXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzObW5KSzVyPUKxNE4yOyCwTR?= NX\5SHdHW0GQR1XS
NCI-H1155 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTw[IxJUUN3ME2yN|AvOzJibl2= MWTTRW5ITVJ?
COR-L279 M3fxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHrd3pnUUN3ME2yOVIvOTdibl2= MYXTRW5ITVJ?
NCI-H1299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfVV5BKSzVyPUK2NU44OSCwTR?= M1e3enNCVkeHUh?=
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PONmlEPTB;Mk[zMlc2KG6P NGm4RodUSU6JRWK=
SK-MEL-2 M1ux[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nUcmlEPTB;MkixMlkhdk1? M{iyUnNCVkeHUh?=
KASUMI-1 NYLmT45DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32wS2lEPTB;MkizMlA2KG6P MmXqV2FPT0WU
NCI-H187 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ6Nz6wPEBvVQ>? MV3TRW5ITVJ?
NCI-H2171 NXSwNnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPRbJBKSzVyPUK4PE46OiCwTR?= NHL0fnJUSU6JRWK=
LNCaP-Clone-FGC NIjuS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3yRYw5UUN3ME2yPVUvOjZibl2= MliwV2FPT0WU
NCI-H1522 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TIWmlEPTB;M{C3MlA2KG6P M3j2XXNCVkeHUh?=
SCH NVPhV5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nEWGlEPTB;M{KyMlIzKG6P M1\FOnNCVkeHUh?=
THP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmwO2M6UUN3ME2zNlIvPiCwTR?= MlTZV2FPT0WU
SNU-C1 NUPF[pY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\EdplKSzVyPUO2Nk4xQSCwTR?= M{CwTnNCVkeHUh?=
CA46 NV\HUlVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTN5Mz62N{BvVQ>? M4jDV3NCVkeHUh?=
NCI-H1963 NY\HfXBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfmfItKSzVyPUO4Ok4yQSCwTR?= NUO4T3dNW0GQR1XS
DEL MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXu[oNNUUN3ME2zPVEvOjdibl2= MXHTRW5ITVJ?
TUR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3PPXNKSzVyPUO5Ok43OSCwTR?= M3nP[3NCVkeHUh?=
NCI-H226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD12MEOuNlMhdk1? MlX2V2FPT0WU
COLO-668 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZTWM2OD12MEOuOVchdk1? NX70S41wW0GQR1XS
CPC-N M2DRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRyMz63O{BvVQ>? M1LUb3NCVkeHUh?=
NCI-H889 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrpfpdKSzVyPUS2NU46OiCwTR?= MYnTRW5ITVJ?
J-RT3-T3-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MortTWM2OD13M{KuOVchdk1? M4ey[nNCVkeHUh?=
MSTO-211H NF;LUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XCW2lEPTB;NUe0MlI3KG6P NH7j[|RUSU6JRWK=
SCC-15 NHPuW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfLd5hCUUN3ME22OlcvPDdibl2= NHfPS5hUSU6JRWK=
SUP-T1 NUO1PXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn3TWM2OD14OE[uNFQhdk1? NUH2Z5lrW0GQR1XS
DMS-153 NXK2TXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHCTWM2OD15NE[uPFMhdk1? MYjTRW5ITVJ?
MS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln5TWM2OD15NUmuOFIhdk1? NH\Lfo5USU6JRWK=
TC-YIK NHz2U2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL4TWM2OD15OEGuNFEhdk1? NX\mN2I2W0GQR1XS
RPMI-8866 NVG4bVVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12yU2lEPTB;MUCwOk4zQCEQvF2= NWe3PVJtW0GQR1XS
KY821 NFfZe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O4cmlEPTB;MUCzOk4xPCEQvF2= MYjTRW5ITVJ?
P31-FUJ NIDUZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjOVVZKSzVyPUGxNVIvPzVizszN MXHTRW5ITVJ?
COLO-824 M3ntcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{NkGuO|gh|ryP Mn;yV2FPT0WU
U-698-M MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnBcJJbUUN3ME2yNlYzNjF3IN88US=> M1P0SHNCVkeHUh?=
TE-441-T NXPJNIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ3MkGuO{DPxE1? MVHTRW5ITVJ?
IMR-5 M4nXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTuPIJWUUN3ME2zOFA6NjZ{IN88US=> NU[xXHh6W0GQR1XS
NCI-H1838 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\H[3JZUUN3ME20NVg3NjN{IN88US=> MlW4V2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Bortezomib单一用药的抗癌作用已在多发性骨髓瘤的异种移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,头颈癌,和结肠癌,以及在黑色素瘤中得到证实。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起肿瘤生长延迟,并减少转移数量。Bortezomib单一用药, 高达5 mg/kg剂量时显著降低乳腺癌细胞的存活率。在前列腺癌小鼠异种移植模型中,Bortezomib (1.0 mg/kg,每周一次)用药4周减少60%肿瘤生长。1.0 mg/kg Bortezomib给药4周导致胰腺癌小鼠异种移植物生长减少72%或84%,并导致肿瘤细胞凋亡增加。1.0 mg/kg Bortezomib显著抑制人浆细胞瘤异种移植物生长,增加肿瘤细胞凋亡和总存活率,并减少肿瘤血管生成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

动力学法:

在典型的动力学试验中,2.00 mL试验缓冲液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL荧光比色皿中,并将比色皿放置于荧光分光光度计的夹套细胞皿座。反应温度通过循环水浴维持在37℃。反应溶液达到热平衡后(5 分钟),1 μL−10 μL储存酶溶液加入培养皿。伴随AMC 从多肽AMC底物裂解的反应进程通过440 nm (λex= 380 nm)下荧光发射的增加监测。
细胞实验:

[5]

+ 展开
  • Cell lines: 人多发性骨髓瘤细胞系U266
  • Concentrations: ~10 μM
  • Incubation Time: 2天
  • Method:

    通过测定细胞吸收 MTT染料的情况而测定 Bortezomib对 MM和 BMSC 生长的抑制情况。每孔使用10 μL 5 mg/mL MTT对培养48小时的细胞进行脉冲处理,至少处理4小时, 随后加入100 μL 含0.04 N HCl的异丙醇 。使用分光光度计在 570 nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 人浆细胞瘤异种移植物RPMI 8226
  • Formulation: 生理盐水
  • Dosages: 1mg/kg
  • Administration: i.v.,一周两次,使用4周,然后一周一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 384.24
化学式

C19H25BN4O4

CAS号 179324-69-7
稳定性 powder
in solvent
别名 LDP-341, MLM341

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT02195479 Active not recruiting Multiple Myeloma Janssen Research & Development LLC December 9 2014 Phase 3
NCT01449344 Active not recruiting Mantle Cell Lymphoma Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance Pierre Benite|European Mantle Cell Lymphoma Network May 9 2009 Phase 3
NCT00703664 Completed Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma National Cancer Institute (NCI) July 9 2008 Phase 2
NCT01965977 Recruiting Diffuse Large B Cell Lymphoma Samsung Medical Center|Janssen LP April 8 2015 Phase 2
NCT01818752 Completed Multiple Myeloma Amgen July 8 2013 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Bortezomib (PS-341) | Bortezomib (PS-341)供应商 | 采购Bortezomib (PS-341) | Bortezomib (PS-341)价格 | Bortezomib (PS-341)生产 | 订购Bortezomib (PS-341) | Bortezomib (PS-341)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID